Skip to main content
Tech.euFundingExplorerBeta

Ventura BioMed

Investor profile

Venture capital

Ventura BioMed has backed 2 European tech companies across 2 funding rounds between 2021 and 2022, joining rounds totalling €46M. Most active in Healthtech. Data as of 4 Nov 2026.

Deals
2
distinct rounds
Companies
2
backed
Active span
2021–2022
2 yrs
Total round €
€46M
sum of rounds joined

Deals by year

distinct rounds / year
Ventura BioMed — deals by year — interactive chart.
Data table
Ventura BioMed — deals by year
20211
20221

Top sectors

by deals
Ventura BioMed — top sectors — interactive chart.
Data table
Ventura BioMed — top sectors
Healthtech2

Stages

by deals
Ventura BioMed — stages — interactive chart.
Data table
Ventura BioMed — stages
Other1
Series A1

Countries

by deals
Ventura BioMed — countries — interactive chart.
Data table
Ventura BioMed — countries
Germany2

Co-investment network

shared rounds
Co-investment network — interactive chart.
Ventura BioMed — 2 dealsVentura BioMedHigh-Tech Gründerfonds (HTGF) — 2 shared deals · click to openHigh-Tech Gründerfonds (HTGF)Boehringer Ingelheim Venture Fund — 1 shared deals · click to openBoehringer Ingelheim Venture FundCoparion — 1 shared deals · click to openCoparionEIC Fund — 1 shared deals · click to openEIC FundGründerfonds Ruhr — 1 shared deals · click to openGründerfonds RuhrHx Bio Ventures — 1 shared deals · click to openHx Bio VenturesInitiative for Industrial Innovators — 1 shared deals · click to openInitiative for Industrial InnovatorsNRW.BANK — 1 shared deals · click to openNRW.BANKSeventure Partners — 1 shared deals · click to openSeventure PartnersVerve Ventures — 1 shared deals · click to openVerve Ventures

Hover a node for shared-deal counts; click a co-investor to open its profile.

Best viewed on a larger screen.

Portfolio

top 30 by total round €
CompanyCountryRoundsTotal €
Abalos TherapeuticsGermany1€43M
IrubisGermany1€2.8M

Biggest deals

top 10 by amount
CompanyStageAmountDate
Abalos TherapeuticsSeries A€43M2021-10
IrubisOther€2.8M2022-10
← Back to investors